Using serum a-fetoprotein for prognostic prediction in patients with hepatocellular carcinoma: What is the most optimal cutoff?

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Hsu, Chia Yang ^a,b,c   Liu, Po Hong ^a,b   Lee, Yun Hsuan ^a,b   Hsia, Cheng Yuan ^a,b   Huang, Yi Hsiang ^a,b   Lin, Han Chieh ^a,b   Chiou, Yi You ^a,b   Lee, Fa Yauh ^a,b   Huo, Teh Ia ^a,b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN;

ADULT; AGED; ALPHA FETOPROTEIN BLOOD LEVEL; ARTICLE; ASCITES; CANCER PROGNOSIS; CANCER SURVIVAL; DISEASE ASSOCIATION; FEMALE; FUNCTIONAL STATUS; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTION; PROSPECTIVE STUDY; SURVIVAL PREDICTION; TAIWAN; TUMOR INVASION; TUMOR VOLUME; VASCULAR DISEASE; BLOOD; BLOOD ANALYSIS; CARCINOMA, HEPATOCELLULAR; COHORT ANALYSIS; LIVER NEOPLASMS; METABOLISM; MIDDLE AGED; PROGNOSIS; PROPENSITY SCORE; STANDARD; STANDARDS; SURVIVAL;

ALPHA-FETOPROTEINS; BLOOD CHEMICAL ANALYSIS; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROPENSITY SCORE; REFERENCE STANDARDS; SURVIVAL ANALYSIS;

EID: 84929192849     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0118825     Document Type: Article

References (26)

1. El-Serag HB, Marrero JA, Rudolph L, Reddy KR (2008) Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 134:1752-1763. doi: 10.1053/j.gastro.2008.02.090 PMID: 18471552
2. Ramirez AG, Weiss NS, Holden AE, Suarez L, Cooper SP, et al. (2012) Incidence and risk factors for hepatocellular carcinoma in Texas Latinos: implications for prevention research. PLoS One 7:e35573. doi: 10.1371/journal.pone.0035573 PMID: 22530052
3. Lok AS, Sterling RK, Everhart JE, Wright EC, Hoefs JC, et al. (2010) Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology 138:493-502. doi: 10.1053/j.gastro.2009.10.031 PMID: 19852963
4. Shim JH, Yoon DL, Han S, Lee YJ, Lee SG, et al. (2012) Is serum alpha-fetoprotein useful for predicting recurrence and mortality specific to hepatocellular carcinoma after hepatectomy? A test based on propensity scores and competing risks analysis. Ann Surg Oncol 19:3687-3696. doi: 10.1245/s10434- 012-2416-1 PMID: 22644512
5. Toyoda H, Kumada T, Kaneoka Y, Osaki Y, Kimura T, et al. (2008) Prognostic value of pretreatment levels of tumor markers for hepatocellular carcinoma on survival after curative treatment of patients with HCC. J Hepatol 49:223-232. doi: 10.1016/j.jhep.2008.04.013 PMID: 18571271
6. Hakeem AR, Young RS, Marangoni G, Lodge JP, Prasad KR (2012) Systematic review: the prognostic role of alpha-fetoprotein following liver transplant for hepatocellular carcinoma. Aliment Pharmacol Ther 35:987-999. doi: 10.1111/j.1365-2036.2012.05060.x PMID: 22429190
7. Merani S, Majno P, Kneteman NM, Berney T, Morel P, et al. (2011) The impact of waiting list alpha-fetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma. J Hepatol 55:814-819. doi: 10.1016/j.jhep.2010.12.040 PMID: 21334400
8. Blank S, Wang Q, Fiel MI, Luan W, Kim KW, et al. (2014) Assessing Prognostic Significance of Preoperative Alpha-Fetoprotein in Hepatitis B-Associated Hepatocellular Carcinoma: Normal is not the New Normal. Ann Surg Oncol 21:986-994. PMID: 24232510
9. Sotiropoulos GC, Lang H, Nadalin S, Neuhauser M, Molmenti EP, et al. (2007) Liver transplantation for hepatocellular carcinoma: University Hospital Essen experience and metaanalysis of prognostic factors. J Am Coll Surg 205:661-675. PMID: 17964442
10. The Cancer of the Liver Italian Program (CLIP) Investigators (2000) Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology 31:840-845. PMID: 10733537
11. Hsu CY, Huang YH, Hsia CY, Su CW, Lin HC, et al. (2010) A new prognostic model for hepatocellular carcinoma based on total tumor volume: the Taipei Integrated Scoring System. J Hepatol 53:108-117. doi: 10.1016/j.jhep.2010.01.038 PMID: 20451283
12. Hsu CY, Lee YH, Huang YH, Hsia CY, Su CW, et al. (2013) Ascites in patients with hepatocellular carcinoma: prevalence, associated factors, prognostic impact, and staging strategy. Hepatol Int 7:188-198.
13. Lee YH, Hsu CY, Huang YH, Su CW, Lin HC, et al. (2012) Selecting a prognostic renal surrogate for patients with hepatocellular carcinoma undergoing transarterial chemoembolization. J Gastroenterol Hepatol 27:1581-1588. doi: 10.1111/j.1440-1746.2012.07151.x PMID: 22497632
14. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, et al. (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35:421-430. PMID: 11592607
15. Bruix J, Sherman M (2005) Management of hepatocellular carcinoma. Hepatology 42:1208-1236. PMID: 16250051
16. Lee YH, Hsu CY, Hsia CY, Huang YH, Su CW, et al. (2013) Alcoholism worsens the survival of patients with hepatitis B virus and C virus-related hepatocellular carcinoma. Hepatol Int 7:645-654.
17. Hsu CY, Lee YH, Hsia CY, Huang YH, Su CW, et al. (2013) Performance status in patients with hepatocellular carcinoma: determinants, prognostic impact, and ability to improve the Barcelona Clinic Liver Cancer system. Hepatology 57:112-119. doi: 10.1002/hep.25950 PMID: 22806819
18. Gonwa TA, Jennings L, Mai ML, Stark PC, Levey AS, et al. (2004) Estimation of glomerular filtration rates before and after orthotopic liver transplantation: evaluation of current equations. Liver Transpl 10:301-309. PMID: 14762871
19. Austin PC (2014) A comparison of 12 algorithms for matching on the propensity score. Stat Med 33:1057-1069. doi: 10.1002/sim.6004 PMID: 24123228
20. Hsu CY, Lee YH, Hsia CY, Huang YH, Su CW, et al. (2013) Performance status enhances the selection of treatment for patients with hepatocellular carcinoma within the milan criteria. Ann Surg Oncol 20:2035-2042. doi: 10.1245/s10434-012-2847-8 PMID: 23306955
21. Mitsuhashi N, Kobayashi S, Doki T, Kimura F, Shimizu H, et al. (2008) Clinical significance of alpha-fetoprotein: involvement in proliferation, angiogenesis, and apoptosis of hepatocellular carcinoma. J Gastroenterol Hepatol 23:e189-197. doi: 10.1111/j.1440-1746.2008.05340.x PMID: 18466288
22. Yang X, Zhang Y, Zhang L, Zhang L, Mao J (2008) Silencing alpha-fetoprotein expression induces growth arrest and apoptosis in human hepatocellular cancer cell. Cancer Lett 271:281-293. doi: 10.1016/j.canlet.2008.06.017 PMID: 18657899
23. Tangkijvanich P, Anukulkarnkusol N, Suwangool P, Lertmaharit S, Hanvivatvong O, et al. (2000) Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels. J Clin Gastroenterol 31:302-308. PMID: 11129271
24. Yamashita T, Ji J, Budhu A, Forgues M, Yang W, et al. (2009) EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 136:1012-1024. doi: 10.1053/j.gastro.2008.12.004 PMID: 19150350
25. Wang Y, Chen Y, Ge N, Zhang L, Xie X, et al. (2012) Prognostic significance of alpha-fetoprotein status in the outcome of hepatocellular carcinoma after treatment of transarterial chemoembolization. Ann Surg Oncol 19:3540-3546. doi: 10.1245/s10434-012-2368-5 PMID: 22532305
26. Fujiki M, Takada Y, Ogura Y, Oike F, Kaido T, et al. (2009) Significance of des-gamma-carboxy prothrombin in selection criteria for living donor liver transplantation for hepatocellular carcinoma. Am J Transplant 9:2362-2371. doi: 10.1111/j.1600-6143.2009.02783.x PMID: 19656125